Controlling T cell–tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy

Y Yuxuan Zhang (College of Chemistry) J Jinjin Wang (School of Pharmaceutical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences) G Guangchao Qing (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) Y Yongchao Wang X Xianlei Li (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) T Ting Luo Y Yi-Feng Wang (State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry) L Lu Liu Y Yufei Wang (Chemistry Division) Q Qiankun Ni (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) S Shuyi Li (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) J Junge Chen (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) F Fangzhou Li (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology) W Weisheng Guo (Translational Medicine Center, Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and The Second Affiliated Hospital, Guangzhou Medical University) J Jinchao Zhang (State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, College of Chemistry and Environmental Science, Hebei University) N Ningqiang Gong (Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States) X Xing-Jie Liang (Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology)

Abstract

Cancer immunotherapy has shown tremendous promise in various cancers. However, current strategies, such as immune checkpoint blockade, primarily restore exhausted T cells but provide only transient efficacy, as the rapid clearance of antibodies. Their limited durability is further hindered by persistent T cell-tumor cell interactions that accelerate T cell exhaustion. To prevent T cells from sustained exposure to these interactions, we present a hydrogel-based biomimetic physical barrier (BPB) here to create a “protective zone” for T cells. The BPB temporarily blocks T cell-tumor cell interactions and shields T cells from inactivation and exhaustion, allowing them to accumulate and maintain their functional activity in the tumor microenvironment. After sufficient T cell accumulation, the dismantling of BPB triggered by near-infrared light irradiation-induced gel-sol transition will restore the interaction between T cells and tumor cells. This controlled re-exposure allows the accumulated T cells to attack the tumor cells in a more activated and anti-exhaustion state, maximizing their tumor-killing potential. Moreover, BPB not only enhances immediate tumor regression but also triggers systemic immune activation and durable memory responses, enabling long-term protection against tumor rechallenge and effective control of multifocal tumors. Collectively, our BPB for modulating the T cell-tumor cell interaction has great prospects for advancing cancer immunotherapy.

Article Details

Volume / Issue Vol. 122, Issue 28
Published July 15, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (17)

Y

Yuxuan Zhang

College of Chemistry

J

Jinjin Wang

School of Pharmaceutical Sciences, Tianjian Laboratory of Advanced Biomedical Sciences

G

Guangchao Qing

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

Y

Yongchao Wang

X

Xianlei Li

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

T

Ting Luo

Y

Yi-Feng Wang

State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry

L

Lu Liu

Y

Yufei Wang

Chemistry Division

Q

Qiankun Ni

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

S

Shuyi Li

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

J

Junge Chen

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

F

Fangzhou Li

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology

W

Weisheng Guo

Translational Medicine Center, Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and The Second Affiliated Hospital, Guangzhou Medical University

J

Jinchao Zhang

State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, College of Chemistry and Environmental Science, Hebei University

N

Ningqiang Gong

Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

X

Xing-Jie Liang

Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology